Vote on NJ bill to bar certain vaccine exemptions stalled
Top New Jersey lawmakers say a bill to end most religious exemptions for vaccines for schoolchildren failed to get enough support and was not formally given a vote
The Gaithersburg biotech's latest move reflects its fundamental strategy: Watch for opportunities to address a virus outbreak.
Companies aim to have vaccine in production within 16 weeks before entering testing stageThere are no vaccines or treatments approved for the new coronavirus, but the race is on to develop one.This week the Coalition for Epidemic Preparedness Innovations (Cepi)announced it would commit $11m ( £8.4m) to three programmes led by the companies Inovio Pharmaceuticals, Moderna and the University of Queensland.Continue reading...
lde;o LGP Abstract Varicella in adults and immunocompromised patients can be severe. The clinical diagnosis of varicella has high accuracy and the history of disease has a high positive predictive value for protection. A significant portion of adults, however, cannot remember if they have had varicella, especially older individuals. We conducted a cross-sectional study to determine the seroprevalence of varicella protective antibodies titers in adults with no clinical history of disease, attended at a Reference Center for Special Immunobiologicals and Travel Medicine in Rio de Janeiro (Brazil). Titration of immuno...
What is a coronavirus? Coronaviruses are a group of viruses that cause diseases in mammals, including humans, and birds. Why are they called coronaviruses? The name derives from the fact that the viral capsule has a “halo” or “crown” surrounding it. What do coronaviruses do? In humans, the virus infects the airways giving rise to flu-like symptoms, a runny nose, cough, sore throat and fever, these are usually mild, but in rare cases can be lethal. Is there a vaccine against coronaviruses? No. Are there any drugs to block or treat infection? No. When were coronaviruses first discovered? In the 1960s ...
In a clinical trial of patients vaccinated after chemotherapy-induced remission with patient-derived AML cells fused with autologous dendritic cells (DC/AML fusions) we demonstrated durable AML-specific immunity. 71% of patients sustained long-term remission from AML at 55-91 months (responders) while those who experienced relapse had recurrence at 2-26 months (non-responders).
Children undergoing hematopoietic stem cell transplant (HSCT) lose their prior immunity post-allogeneic transplant and need reimmunization post-transplant. Traditionally, immunizations post-HSCT were administered at a pediatrician's office (PO), but studies in adult patients have shown compliance with re-vaccination to be low and no data exists on adherence in pediatrics. An internal audit of HSCT patients who received vaccinations at a PO revealed delays in starting vaccines when eligible, non-completion of the schedule in its entirety happened often, and there was an extended length of time for completion of the schedule.
CAR T cells have demonstrated unique potency for tumor cytoreduction and durable response in hematological malignancies. However, disease relapse remains a concern due to the emergence of antigen negative variants, tolerization of CAR T cell populations and lack of T cell persistence. We postulated that vaccination with a personalized cancer vaccine, that we developed, in which patient derived tumor cells are fused with autologous dendritic cells would enhance CAR T cell efficacy through the expansion of T cell clonal populations and the vaccine mediated enhancement of T cell activation and persistence.
Given the significant morbidity from infection after HCT, guidelines have recommended re-vaccination starting at 6 to 12 months post-tx. Guideline adherence, however, has been varied across institutions.
BMT CTN 1401 is an academically led randomized study of a personalized cancer vaccine in which the combination of DC/MM fusion vaccine and lenalidomide maintenance after autoHCT is compared with maintenance alone as upfront treatment of MM (NCT#02728102). Assessment of the percentage of patients achieving CR and therapy-induced changes in MM-specific immunity are the primary clinical and immunologic endpoints, respectively. The protocol represents a transformative open source approach to cell therapy in MM and required collection of tumor cells prior to treatment initiation and vaccine production at day 60 after autoHCT.
Our personalized cancer vaccine comprises patient tumor cells fused with autologous dendritic cells (DCs) and limits the risk of antigen escape by presenting a broad array of tumor antigens in the context of DC mediated co-stimulation. In clinical trials of hematologic malignancies patients, vaccination induced expansion of tumor-specific T cells (Tc) and led to prolonged remission in a subset of patients. Currently, we are developing a novel second-generation (2G) vaccine. Fusions are presented in the context of a unique biomatrix expressing high levels of 41BB ligand (41BBL), to further accentuate Tc activation.